Genmab A/S
F:GE91
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Genmab A/S
F:GE91
|
DK |
|
Intelligo Technology Inc
TWSE:7749
|
KY |
|
F
|
Factset Research Systems Inc
XMUN:FA1
|
US |
|
Virgin Galactic Holdings Inc
F:0QL0
|
US |
|
L
|
Lynas Rare Earths Ltd
F:LYI
|
MY |
|
Tallink Grupp AS
F:T5N
|
EE |
|
A
|
American Water Works Company Inc
XMUN:AWC
|
US |
|
K
|
Kerry Group PLC
DUS:KRZ
|
IE |
|
A
|
Aeon Co Ltd
XMUN:JUS1
|
JP |
|
C
|
Canadian Tire Corporation Ltd
F:YAAA
|
CA |
|
U
|
United Internet AG
F:UTDI
|
DE |
|
B
|
BHP Group Ltd
DUS:BHP
|
AU |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GE91's stock price target?
Price Target
33.51
EUR
According to Wall Street analysts, the average 1-year price target for 
GE91 is 33.51 EUR with a low forecast of 18.58 EUR and a high forecast of 40.43 EUR.
What is the Revenue forecast for Genmab A/S?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 10%.
What is the Gross Profit forecast for Genmab A/S?
Projected CAGR
7%
The compound annual growth rate for Gross Profit over the next 8 years is 7%.
What is the Operating Income forecast for Genmab A/S?
Projected CAGR
10%
The compound annual growth rate for Operating Income over the next 8 years is 10%.
What is the Pre-Tax Income forecast for Genmab A/S?
Projected CAGR
20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 20%.
What is the Net Income forecast for Genmab A/S?
Projected CAGR
12%
The compound annual growth rate for Net Income over the next 8 years is 12%.